1LEVER A F, HOLE D J, GILLIS C R, et al. Do inhibitors of angiotensin- I -converting enzyme protect against risk of cancer[ J ]. Lancet, 1998, 352(9123) :179-184.
2KOSUGI M, MIYAJIMA A, KIKUCHI E, et al. Angiotensin Ⅱ type I receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer[ J]. Clin Cancer Res, 2006, 12(9) :2888-2893.
3SUGANUMA T, INO K, SHIBATA K, et al. Functional expression of the angiotensin Ⅱ type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination [ J ]. Clin Cancer Res, 2005, 11 (7) :2686-2694.
5ROUSSEAU S,HOULE F, LANDRY J, et al. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells [ J ]. Oncogene, 1997, 15(18):2169.
6Munoz N,Franceschi S.Epidemiology of gastric cancer and perspectives for prevention.Salud Publica Mex 1997;39:318-330.
7Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world.J Clin Oncol 2006;24:2137-2150.
8Glimelius B,Ekstrom K,Hoffman K,Graf W,Sjodén PO,Haglund U,Svensson C,Enander LK,Linné T,Sellstrom H,Heuman R.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.Ann Oncol 1997;8:163-168.
2Koizum iW.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase In trial[J].Lancel Oncol, 2008.
